Lantern Pharma Inc. (LTRN) Bundle
Understanding Lantern Pharma Inc. (LTRN) Revenue Streams
Understanding Lantern Pharma Inc.’s Revenue Streams
As of September 30, 2024, Lantern Pharma Inc. has not recognized any revenue for the three and nine-month periods ended September 30, 2024, and 2023. The company primarily operates in the biotechnology sector, focusing on developing targeted cancer therapies.
Breakdown of Primary Revenue Sources
Currently, Lantern Pharma's revenue streams are nonexistent, as they have not generated any revenue from product sales. The only income recognized to date has been from prior research grants. Therefore, the breakdown of revenue sources remains limited to potential future product revenues which have yet to materialize.
Year-over-Year Revenue Growth Rate
Due to the absence of recognized revenues, the year-over-year revenue growth rate remains at 0% for the periods ending September 30, 2024, and 2023.
Contribution of Different Business Segments to Overall Revenue
As there are currently no revenue-generating segments, the contribution from different business segments to overall revenue is 0%. The company continues to focus on research and development activities without any sales revenue.
Analysis of Any Significant Changes in Revenue Streams
There have been no significant changes in revenue streams as the company has consistently reported no revenue for the past several quarters. The focus remains on advancing clinical trials and developing drug candidates, with expectations to generate revenue only upon successful commercialization of these products.
| Period | Revenue Recognized | Net Loss | Net Loss per Share |
|---|---|---|---|
| Three Months Ended September 30, 2024 | $0 | $(4,505,697) | $(0.42) |
| Three Months Ended September 30, 2023 | $0 | $(3,161,450) | $(0.29) |
| Nine Months Ended September 30, 2024 | $0 | $(14,906,013) | $(1.39) |
| Nine Months Ended September 30, 2023 | $0 | $(11,775,613) | $(1.08) |
The lack of revenue generation reflects the company's current stage in the development pipeline, where substantial investments are being made in research and clinical trials. The company anticipates potential future revenues contingent upon successful drug development and regulatory approvals.
A Deep Dive into Lantern Pharma Inc. (LTRN) Profitability
A Deep Dive into Lantern Pharma Inc.'s Profitability
Gross Profit Margin: The gross profit margin for the nine months ended September 30, 2024, was 0% as there were no revenues reported during this period. This was consistent with the nine months ended September 30, 2023, which also reported a gross profit margin of 0%.
Operating Profit Margin: The operating loss for the nine months ended September 30, 2024, amounted to ($16,320,038), resulting in an operating profit margin of -100%. This reflects an increase from the operating loss of ($13,000,186) for the same period in 2023, maintaining a similar operating profit margin of -100%.
Net Profit Margin: The net loss for the nine months ended September 30, 2024, was ($14,906,013), translating to a net profit margin of -100%. This was an increase in net loss compared to ($11,775,613) for the nine months ended September 30, 2023, also reflecting a net profit margin of -100%.
Trends in Profitability Over Time
The net losses have consistently increased over the past year. For the nine months ended September 30, 2024, the net loss was $14,906,013, compared to $11,775,613 for the same period in 2023, marking an increase of approximately 26%.
Comparison of Profitability Ratios with Industry Averages
As a clinical-stage biotechnology company, Lantern Pharma does not yet generate revenue, which significantly impacts its profitability ratios. The industry average for net profit margins in the biotechnology sector typically ranges from -10% to -40% depending on the stage of development and commercialization of products.
Analysis of Operational Efficiency
The total operating expenses for the nine months ended September 30, 2024, were $16,320,038, up from $13,000,186 in the same period for 2023, primarily driven by increased research and development expenses.
| Metric | 2024 (9 Months) | 2023 (9 Months) |
|---|---|---|
| Gross Profit Margin | 0% | 0% |
| Operating Loss | ($16,320,038) | ($13,000,186) |
| Net Loss | ($14,906,013) | ($11,775,613) |
| Operating Profit Margin | -100% | -100% |
| Net Profit Margin | -100% | -100% |
The increase in operational expenses reflects the company's ongoing investment in research and development, with total R&D expenses for the nine months ended September 30, 2024, amounting to $11,856,169, compared to $8,321,058 in the prior year.
Debt vs. Equity: How Lantern Pharma Inc. (LTRN) Finances Its Growth
Debt vs. Equity: How Lantern Pharma Inc. Finances Its Growth
As of September 30, 2024, Lantern Pharma Inc. reported a total debt of $0, indicating a reliance on equity financing for its operations and growth. The company has not issued any long-term or short-term debt, emphasizing a purely equity-based capital structure.
In terms of equity, as of September 30, 2024, the total stockholders' equity stood at $26,598,221, down from $40,907,934 at the end of 2023. The decline in equity reflects the company's ongoing operational losses and the impact of accumulated deficits.
Debt-to-Equity Ratio and Comparison to Industry Standards
The absence of debt results in a debt-to-equity ratio of 0.00. This is significantly lower than the industry average for biotechnology firms, which typically ranges from 0.20 to 0.50. The lack of leverage may present a lower risk profile but also indicates limited financial flexibility in pursuing growth opportunities.
Recent Debt Issuances and Credit Ratings
Lantern Pharma has not engaged in recent debt issuances, nor does it have any credit ratings due to the absence of outstanding debt obligations. The company continues to fund its operations through equity financing, primarily through the exercise of warrants and stock options.
Balancing Between Debt Financing and Equity Funding
To date, the company has financed its operations primarily through equity. During the nine months ended September 30, 2024, net cash provided by financing activities was approximately $66,710, which was derived from proceeds from warrant exercises. This indicates a strategic preference for equity financing over debt, allowing the company to avoid interest obligations and maintain operational flexibility.
| Financial Metric | Value |
|---|---|
| Total Debt | $0 |
| Total Stockholders' Equity (Sept 30, 2024) | $26,598,221 |
| Debt-to-Equity Ratio | 0.00 |
| Industry Average Debt-to-Equity Ratio | 0.20 - 0.50 |
| Net Cash from Financing Activities (9 months 2024) | $66,710 |
The financial health of Lantern Pharma Inc. reflects a cautious approach towards leveraging, focusing on equity funding to support its growth initiatives in the biotechnology sector.
Assessing Lantern Pharma Inc. (LTRN) Liquidity
Assessing Lantern Pharma Inc.'s Liquidity
Current and Quick Ratios
As of September 30, 2024, Lantern Pharma Inc. reported a current ratio of approximately 6.1, calculated using current assets of approximately $28.1 million and current liabilities of approximately $4.6 million. The quick ratio, which excludes inventory, is similar, reflecting a strong liquidity position.
Analysis of Working Capital Trends
As of September 30, 2024, the company had working capital of approximately $26.3 million. This represents a significant increase compared to $20.8 million reported at the same time in 2023. The growth in working capital indicates improved financial stability and the ability to cover short-term liabilities.
Cash Flow Statements Overview
For the nine months ended September 30, 2024, the cash flow statement indicated:
- Net cash flows used in operating activities: $(13,841,414)
- Net cash flows used in investing activities: $(77,886)
- Net cash flows provided by financing activities: $66,710
- Net decrease in cash and cash equivalents: $(13,834,930)
In comparison, for the nine months ended September 30, 2023, net cash used in operating activities was $(10,961,198), indicating an increase in cash outflow related to operations year-over-year.
Potential Liquidity Concerns or Strengths
The existing cash, cash equivalents, and marketable securities as of September 30, 2024, amount to approximately $28.1 million, which is expected to fund operations for at least the next 12 months. However, the company continues to incur significant operating losses, with a net loss of approximately $(14,906,013) for the nine months ended September 30, 2024, compared to $(11,775,613) for the same period in 2023, raising potential concerns about long-term sustainability if losses continue at this rate.
| Period | Net Cash from Operating Activities | Net Cash from Investing Activities | Net Cash from Financing Activities | Net Change in Cash |
|---|---|---|---|---|
| 9 Months Ended September 30, 2024 | $(13,841,414) | $(77,886) | $66,710 | $(13,834,930) |
| 9 Months Ended September 30, 2023 | $(10,961,198) | $(1,186,391) | $0 | $(12,171,238) |
In summary, while the company's liquidity position appears robust with a solid current ratio and substantial cash reserves, the rising operational cash outflows and continued net losses highlight the need for strategic financial management moving forward.
Is Lantern Pharma Inc. (LTRN) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the following valuation metrics for Lantern Pharma Inc. (LTRN) are available:
- Price-to-Earnings (P/E) Ratio: N/A (the company reported a net loss)
- Price-to-Book (P/B) Ratio: 0.69 (calculated as market capitalization divided by total stockholders’ equity)
- Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: N/A (no EBITDA reported due to net losses)
The stock price trends over the last 12 months show significant volatility:
| Date | Stock Price | Market Capitalization |
|---|---|---|
| September 30, 2023 | $5.00 | $53.93 million |
| December 31, 2023 | $3.50 | $37.65 million |
| March 31, 2024 | $4.20 | $45.15 million |
| June 30, 2024 | $2.80 | $30.09 million |
| September 30, 2024 | $2.45 | $26.45 million |
As of September 30, 2024, the company has not declared any dividends, and therefore the dividend yield and payout ratios are not applicable.
Analyst consensus on stock valuation is mixed:
- Buy: 1 Analyst
- Hold: 3 Analysts
- Sell: 2 Analysts
For the nine months ended September 30, 2024, the company reported:
- Net Loss: $(14,906,013)
- Total Assets: $30,293,264
- Total Liabilities: $3,695,043
- Total Stockholders’ Equity: $26,598,221
Key financial ratios and performance indicators are as follows:
| Metric | Value |
|---|---|
| Net Loss per Share (Basic and Diluted) | $(1.39) |
| Weighted-Average Number of Common Shares Outstanding | 10,755,015 |
| Accumulated Deficit | $(70,150,417) |
| Cash and Cash Equivalents | $8,102,819 |
Overall, the valuation metrics indicate that the company is currently operating at a loss, with no earnings to report. The P/B ratio suggests that the stock may be undervalued relative to its book value, while the lack of dividends points towards reinvestment in growth initiatives. Analyst recommendations reflect cautious optimism amid ongoing operational challenges.
Key Risks Facing Lantern Pharma Inc. (LTRN)
Key Risks Facing Lantern Pharma Inc.
The financial health of Lantern Pharma Inc. (LTRN) is influenced by a variety of internal and external risk factors that could significantly impact its operations and profitability. Below are the key risks identified for the company as of 2024.
Industry Competition
The biotechnology sector is characterized by intense competition, with numerous companies vying for market share in drug development. Lantern Pharma faces competition from both established pharmaceutical companies and emerging biotech firms, which may have more resources, advanced technologies, and established market presence.
Regulatory Changes
Lantern Pharma operates in a heavily regulated environment, and any changes in regulatory frameworks or requirements can affect its ability to conduct clinical trials and bring products to market. The cost and time associated with gaining regulatory approvals can be substantial, and delays or rejections can adversely affect financial performance.
Market Conditions
Fluctuations in market conditions, including economic downturns, can impact investment levels in biotechnology. As of September 30, 2024, Lantern Pharma had total assets of approximately $30.3 million and working capital of approximately $26.3 million. These figures highlight the company's current liquidity position but also underscore the risk associated with reliance on external funding sources for continued operations and growth.
Operational Risks
Operational risks include challenges in executing clinical trials efficiently. Lantern Pharma's research and development expenses increased by approximately 42% from approximately $8.3 million for the nine months ended September 30, 2023, to approximately $11.9 million for the same period in 2024. Such increases can strain financial resources if not managed effectively.
Financial Risks
The company reported net losses of approximately $14.9 million for the nine months ended September 30, 2024, compared to approximately $11.8 million for the same period in 2023. Continued financial losses may necessitate further capital raises, which can dilute existing shareholders and affect stock price stability.
Strategic Risks
Strategic risks involve the potential failure to effectively execute on its business model and growth strategy. The company has not generated significant revenue and relies heavily on capital from equity sales. As of September 30, 2024, Lantern Pharma had approximately $28.1 million in cash, cash equivalents, and marketable securities, which may be insufficient if further capital is not raised in a timely manner.
Mitigation Strategies
To address these risks, Lantern Pharma has implemented several strategies, including:
- Engaging in partnerships and collaborations to share the financial burden of research and development.
- Continuing to explore grant funding and other non-dilutive capital options to support ongoing clinical trials and operations.
- Maintaining a robust pipeline of drug candidates to diversify its operational risks and potential revenue streams.
Quantitative Overview of Financial Data
| Metric | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Total Assets | $30.3 million | $43.6 million |
| Working Capital | $26.3 million | $40.9 million |
| Net Loss | $14.9 million | $11.8 million |
| Research & Development Expenses | $11.9 million | $8.3 million |
| Cash & Cash Equivalents | $28.1 million | $N/A |
Future Growth Prospects for Lantern Pharma Inc. (LTRN)
Future Growth Prospects for Lantern Pharma Inc.
Analysis of Key Growth Drivers
The company is poised for growth through various channels, including product innovations, market expansions, and strategic partnerships. The RADR® platform, which utilizes artificial intelligence and machine learning, underpins the development of new oncology therapies.
Product Innovations
Lantern Pharma is advancing several drug candidates, including:
- LP-300
- LP-184
- LP-284
The ongoing clinical trials for these candidates are expected to enhance the company’s market position significantly.
Market Expansions
The company aims to expand its market reach, particularly in the oncology sector, which is projected to grow substantially. The global oncology market is expected to reach approximately $450 billion by 2028, with a compound annual growth rate (CAGR) of 7.5% from 2021 to 2028.
Future Revenue Growth Projections
For the nine months ended September 30, 2024, the company reported:
- Net loss of $14,906,013
- Operating expenses amounting to $16,320,038
Despite these losses, revenue growth projections indicate potential profitability as clinical trials advance and new products are launched.
Earnings Estimates
Analysts estimate that the company's earnings could improve significantly as it progresses through critical phases of drug development. The projected net loss per share for the nine months ended September 30, 2024, was $1.39, compared to $1.08 for the same period in 2023.
Strategic Initiatives and Partnerships
The collaboration with Actuate Therapeutics is particularly noteworthy. The partnership focuses on developing biomarker-driven signatures for Actuate's product candidates, highlighting the company’s commitment to innovation.
Competitive Advantages
The proprietary RADR® platform provides a competitive advantage by streamlining the drug development process, reducing time and costs associated with traditional methods. This platform enables the identification of potential drug candidates faster and more efficiently.
Table: Financial Overview
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Loss | $4,505,697 | $3,161,450 | Increase of $1,344,247 |
| Operating Expenses | $5,179,576 | $3,523,621 | Increase of $1,655,955 |
| Research and Development Expenses | $3,716,646 | $2,209,894 | Increase of $1,506,752 |
| General and Administrative Expenses | $1,462,930 | $1,313,727 | Increase of $149,203 |
Conclusion
Lantern Pharma Inc. is strategically positioned for future growth with its innovative drug development approach and strong market potential in oncology. The ongoing clinical programs and partnerships will likely enhance its competitive edge and financial performance.
Lantern Pharma Inc. (LTRN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Lantern Pharma Inc. (LTRN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Lantern Pharma Inc. (LTRN)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Lantern Pharma Inc. (LTRN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.